TopFunds

Stryker Corporation

NYSE: SYK

Stock price

341.09 USD

(+0%) TODAY

Health Care EquipmentMedical - DevicesInvestable Universe

Financial Performance

Share

5Y price score: 39

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 216.6%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    281.0

    52-week range

    396.8

    341.09

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    3.6 %

    Dividend Yield TTM

    1 %

    Market cap $

    $ 130,761

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    35.3

    Price / Book TTM

    5.5

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    4.3

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    (9.1) %

    35.4 %

    216.6 %

    Free cash flow per share growth

    23.9 %

    52.7 %

    578.6 %

    Earnings per share growth

    8.2 %

    100 %

    122.2 %

    Founded: 1,941

    Employees: 53,000

    Business Summary:Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q2 (Jul 30, 2026)

    1) Strategy & Leadership - Stryker's recovery from a cybersecurity incident is ongoing, with production ramping up to meet demand. - The company reported strong organic sales growth of 9% in Q2 2026, driven by med surg, neurotechnology, and orthopedics. - The sales force has been stabilized, and the company is optimistic about recapturing lost sales in the peripheral vascular business due to recent supply disruptions.

    2) Financial & Segment Results - Adjusted EPS grew by 17.9% to $3.69, reflecting improved gross margins and operational execution. - Organic sales growth by segment: - MedSurg and Neurotechnology: 9.2% (8.9% U.S., 10.5% international) - Instruments: 8.4% (U.S. growth down from 16.3% YoY) - Endoscopy: 10.2% (strong demand across various areas) - Medical: 13.1% (led by preoperative products) - Orthopedics: 8.6% (U.S. knees grew 6.2%, hips 4.9%) - Vascular: 6.7% decline due to supply issues.

    3) Operational or Product Plans - Stryker is launching several new products, including Mako RPS and Triathlon Gold, with positive early feedback. - The company is focusing on capital equipment, with a strong backlog and elevated demand for products like ProCuity beds. - The procedural environment remains stable, with no significant changes in surgical volume trends observed.

    4) Guidance & Outlook / Investor Angle - Full-year guidance for organic net sales growth is narrowed to 8.3% to 9.3%, with adjusted EPS expected between $14.95 and $15.10. - The company plans to resume share repurchases, leveraging strong cash flow generation and recent valuation compression in the medtech sector. - Stryker remains committed to M&A as a primary capital allocation priority, while also considering opportunistic share buybacks.

    5) Missing Information - The call did not provide specific figures on the impact of the cybersecurity incident on sales or detailed projections for the second half of the year beyond general confidence in recovery.

    Bottom line: Stryker is on track for a strong year despite recent challenges, with solid growth across multiple segments and a focus on new product launches and operational improvements, making it an attractive investment opportunity for shareholders.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Stryker Corporation — Financial Overview, Stock Price, Market Cap

    Stryker Corporation is a company. Founded in 1941. As of August 14, 2026, the company's market capitalization is $130760522311 with a current stock price of $341.09.